lyophilized powder raises a handful of sensible questions. This page answers them in order, starting with the fundamentals and moving to applications.
This page was last updated on 2026-07-17 and is reviewed periodically as new material appears.
Thymosin alpha 1 was identified in 1977 as a component of thymosin fraction 5, a heterogeneous preparation used in early studies of thymic function. Investigators purified the active material and determined its amino acid sequence, which enabled chemical synthesis. Work in the following decades concentrated on T-cell maturation and immune reconstitution in animals and small human cohorts. Early preparations varied in composition, so results from that period are difficult to compare with studies using defined synthetic peptide.
Clinical research has examined the peptide in chronic hepatitis B and C, as a vaccine adjuvant, and in sepsis and oncology settings. Findings across trials are mixed; some report changes in selected immune markers, while others find no clear clinical benefit. Many studies are small and define outcomes differently, which limits comparison. Regulatory approval is confined to a few countries, and the compound is not an approved drug in the United States or most of Europe.
Thymosin alpha-1 is supplied as a lyophilized powder in most research settings. The solid dissolves readily in water and in common aqueous buffers, and it is typically reconstituted shortly before use. Solutions are clear and colourless at ordinary working concentrations. Because the peptide is hygroscopic, weighing and reconstitution are usually performed with minimal exposure to ambient air. Aliquots are prepared to avoid repeated freeze-thaw cycles, and working solutions are kept cold.
Long-term storage is generally at minus twenty degrees Celsius or colder, preferably desiccated and protected from light. Lyophilized material is more stable than reconstituted solution, which degrades faster at room temperature. Stability depends on pH, ionic strength, and the presence of oxidising agents. Published stability data for the peptide are limited, so storage claims in catalogues should be treated as general guidance rather than measured guarantees. Freeze-thaw cycles are kept to a minimum.
Identity and purity are normally confirmed by reversed-phase high-performance liquid chromatography and mass spectrometry. The expected mass for the acetylated 28-residue peptide is close to 3108 daltons, and a mass shift indicates a modification or truncation. Peptide mapping after enzymatic digestion can resolve sequence-level questions. Counter-ion content, water content, and residual solvents are separate quality attributes that a certificate of analysis may or may not report. Aggregation is monitored by size-exclusion chromatography when relevant.
| Property | Value | Notes |
|---|---|---|
| First described | 1977 | Reported as a component of thymosin fraction 5 |
| Sequence length | 28 amino acids | N-terminal residue is acetylated |
| Net charge at neutral pH | Negative | Reflects a high proportion of acidic residues |
| Principal studied uses | Chronic hepatitis B and vaccine adjuvant | Research uses outnumber approved indications |
| Regulatory status | Approved in a limited number of countries | Not approved in the United States or most of Europe |
Thymosin alpha 1 is a short peptide of 28 amino acid residues that derives from the amino terminal region of a larger precursor protein known as prothymosin alpha. The peptide carries an acetyl group on its first residue and contains no disulfide bonds or carbohydrate chains. Its sequence is highly conserved across mammalian species, which is one reason laboratories treat it as a molecule with a defined and reproducible structure rather than a variable tissue extract. The name follows an early naming convention for thymus-derived fractions and does not imply that the peptide acts as a hormone in the classical endocrine sense.
Biologically, the peptide is studied mainly in the context of immune cell development and regulation. It is produced in the thymus and in several other tissues, and it appears to influence the maturation and activity of T cells and other immune populations. Laboratory work describes effects on cytokine production, on the balance between T cell subsets, and on the function of dendritic cells. Much of this evidence comes from cell culture and animal models, so the extent to which the same pathways operate in humans remains an open question.
Laboratory supplies of the peptide usually arrive as a lyophilized powder in sealed vials. The powder is hygroscopic, so a vial should be allowed to reach room temperature before it is opened to prevent condensation on the contents. Weighing and transfer are best performed in a low-humidity environment with clean tools. Once dissolved, the solution should be mixed gently rather than vortexed, because foaming and shear can reduce recovery of the peptide.
Storage recommendations center on low temperature, dryness, and protection from repeated freezing and thawing. The intact powder is commonly held at 20 degrees below zero Celsius or colder, while a working solution is divided into single-use aliquots to limit freeze-thaw cycles. Buffered saline or phosphate-buffered saline at neutral pH is frequently used as a diluent. Light sensitivity is not well documented, yet amber vials or foil wrapping are common practice for long-term storage of peptide stocks.
Within the immune system, the peptide acts on several cell types rather than a single target. Reported activities include promotion of T-cell maturation, enhancement of natural killer cell activity, and modulation of cytokine production by dendritic cells and macrophages. Some of these effects appear to operate through toll-like receptor signaling, though the precise receptor-level mechanism remains debated. Whether the observed immune changes translate into clinical benefit is a separate question and depends on the indication studied.
The peptide was described in the 1970s as a component of thymic extracts, and early research focused on restoring immune function in immunodeficiency states. A synthetic version entered clinical development in the 1980s and is approved as a drug in several countries for conditions such as chronic hepatitis B and certain immunodeficiencies. Approval status varies widely by jurisdiction, and in the United States it is not an approved therapeutic. Regulatory and clinical positions differ, so statements about efficacy should be tied to specific indications and studies.
Identity and purity are usually checked by reverse-phase high-performance liquid chromatography, which separates the intact chain from truncated products, together with mass spectrometry for confirmation of the expected mass. Peptide mapping after enzymatic digestion and amino acid analysis add sequence-level evidence. Release testing also covers water content, residual solvents, and counter-ions, all of which influence measured mass and stability. Related-peptide limits are commonly expressed as a percentage of total peak area, with individual unspecified impurities held below a lower threshold.
The lyophilized peptide is a white to off-white powder that dissolves freely in water and in aqueous buffers near neutral pH. Because the molecule carries a net negative charge under physiological conditions, saline and phosphate solutions are the usual vehicles, while strongly acidic media are avoided. Stock solutions are commonly divided into small aliquots so that repeated freezing and thawing can be limited, since cycling may encourage aggregation. Solubility in organic solvents is poor and those solvents are seldom used as primary diluents.
Recommended storage for the dry powder is a freezer near minus twenty degrees Celsius, kept desiccated and away from light. Once dissolved, the peptide is less stable and is usually held at two to eight degrees Celsius for short intervals or frozen for longer storage. Stability studies focus on the acetylated terminus and the disulfide linkage because those features define the intact molecule. Common degradation routes include cysteine oxidation, deamidation of asparagine or glutamine side chains, and slow formation of higher-molecular-weight species.
BMS-986121: μ-PAM BMS-986122: μ-PAM BPRMU191: confers agonistic properties to small-molecule morphinan antagonists Ignavine Oxytocin: μ-PAM δ-PAM (see reference) Cannabidiol Tetrahydrocannabinol Sodium (Na+)
=== Screening === Cardiovascular system screening is considered mandatory by the EASL, as MASLD outcomes often result in cardiovascular complications, which can manifest as subclinical atherosclerosis, the cause of most MASLD-related deaths. People with MASLD are at high risk for cardiovascular morbidity and mortality, and "aggressive modification of cardiovascular disease risk factors is warranted in all patients" according to AASLD. The AASLD further recommends that people with a cirrhotic MASH be systematically screened for gastric and esophageal varices and liver cancer. They do not recommend routine liver biopsies and screening for liver cancer for non-cirrhotic people with MASH, but such screening sometimes occurs on a case-by-case basis. Also, people with MASLD may be considered for screening for hepatocellular carcinoma (liver cancer) and gastroesophageal varices. The NICE advises regular screening of people with MASLD for advanced liver fibrosis every three years for adults and every two years for children using the enhanced liver fibrosis (ELF) blood test. Follow-up is recommended for people with obesity and insulin resistance using the homeostasis model assessment of insulin resistance (HOMA-IR). People with MASH with fibrosis and hypertension merit closer monitoring, as there is a higher risk of disease progression.
Dorothy Mary Crowfoot Hodgkin (née Crowfoot; 12 May 1910 – 29 July 1994) was an English chemist who advanced the technique of X-ray crystallography to determine the structure of biomolecules, which became essential for structural biology. She received the 1964 Nobel Prize in Chemistry, and is the only British woman scientist to have been awarded a Nobel Prize. Among her most influential discoveries are the confirmation of the structure of penicillin as previously surmised by Edward Abraham and Ernst Boris Chain; and mapping the structure of vitamin B12, for which in 1964 she became the third woman to win the Nobel Prize in Chemistry. Hodgkin also elucidated the structure of insulin in 1969 after 35 years of work. Hodgkin used the name "Dorothy Crowfoot" until twelve years after marrying Thomas Lionel Hodgkin, when she began using "Dorothy Crowfoot Hodgkin". Hodgkin is referred to as "Dorothy Hodgkin" by the Royal Society (when referring to its sponsorship of the Dorothy Hodgkin fellowship), and by Somerville College. The National Archives of the United Kingdom refer to her as "Dorothy Mary Crowfoot Hodgkin". The case of her Nobel prize is inscribed 'Crowfoot Hodgkin'.
Sources: en.wikipedia.org
where CL is total body clearance (L/h), BSA is total body surface area (m2), AAG and ALB represent alpha1 acid glycoprotein and albumin plasma concentrations (g/L) respectively, and AGE is the patients age (years). HEP12 represents a measure of hepatic dysfunction, affecting clearance of docetaxel. This final model accounted for a modest proportion of patients and identified most of the patients varying from the model (population median of CL = 35.6 L/h) as having hepatic dysfunction, indicating hepatic function as the most unpredictable factor with regards to clearance variability. Patients with significant hepatic dysfunction had an approximately 30% decrease in clearance of docetaxel and were also at a higher risk of toxicity poisoning from docetaxel treatment. Clearance has been shown from population pharmacokinetic studies to decrease significantly with age, increased alpha1 acid glycoprotein and albumin concentrations and decreased body surface area. Renal impairment is unlikely to affect metabolism or excretion of docetaxel as renal excretion contributes less than 5% of elimination. Limited data is available for docetaxel use in children with dosage between 55 and 75 mg/m2. Two paediatric studies have taken place that show a mean clearance of 33 L/h/m2 and concentration-time profiles best fitted by a two-compartmental model of distribution and elimination. Mean distribution half-life was 0.09 hours and mean elimination half-life was 1.4 hours in paediatric studies.
(1887), banker, prominent figure in Thoroughbred horse racing Richard Stevens (1890), attorney and real estate developer in Hoboken, New Jersey, grandson of inventor John Stevens and son of Stevens Institute of Technology founder Edwin Augustus Stevens Cortlandt F. Bishop (1891), aviator and book collector, grandson of philanthropist Benjamin Hazard Field Howard Gould* (1894), financier, son of railroad tycoon Jay Gould Joseph Peter Grace Sr. (1894), businessman, polo player, heir to W. R. Grace and Company; founder of Pan American-Grace Airways and Grace National Bank Samuel Bloomingdale (1895), businessman, heir to the Bloomingdale's department store fortune Dexter M. Ferry Jr. (1898), director of D.M. Ferry & Co.; member of the Michigan House of Representatives Charles A. Dana (1902), philanthropist who founded the Dana Foundation and Dana Holding Corporation John Knowles Fitch (1902), founder of Fitch Ratings, one of the Big Three rating agencies Marcellus Hartley Dodge Sr. (1903), chairman of the Remington Arms Company, husband of Geraldine Rockefeller Dodge George Earle Warren (1903), vice president of Chase Manhattan Bank Pendleton Dudley (1906), public relations executive, founder of Dudley-Anderson-Yutzy William Gage Brady Jr.
MedPlus Health Services is an Indian pharmacy retail chain, headquartered in Hyderabad. MedPlus is the second largest pharmacy chain in India, operating over 5,500+ pharmacy stores across 800+ cities, as of 2026. MedPlus sells prescription and OTC medicines, FMCG products, vitamins and other nutrition supplements, and opticals. It also offers clinical laboratory services and physician consultation services in Hyderabad, Vijayawada and Bangalore. The company owns and runs ePharmacy and an online clinical lab service.
Sources: en.wikipedia.org
=== Presence in livestock species during gestation === Bovine/Ovine RBP, identical to that found in plasma has been identified in the placental tissues of both the ovine and the bovine, suggesting that RBP may be highly involved in retinol transport and metabolism during pregnancy. However, exact timing of expression had been yet to be identified. An antiserum specific for bovine conceptus RBP and immunohistochemistry has been utilized to identify the presence of RBP at different stages of early pregnancy. Strong immunostaining and hybridization were observed in the trophectoderm of tubular, but not spherical blastocysts at day 13. RBP mRNA was localized to epithelial cells of the chorion, allantois, and amnion at day 45 of pregnancy. Lastly, RBP mRNA was detected in the cotyledons, the fetal contribution to the placenta and the site of attachment to the uterine epithelium for fetal/maternal exchange. Expression of RBP in developing conceptuses, extraembryonic membranes, and at the fetal-maternal interface indicate that there may be some regulation of retinol transport and metabolism that occurs due to RBP by the extraembryonic membranes. Within the uterus of pregnant bovines, it has been found that RBP synthesis in the luminal and glandular epithelium is quite similar to that of a cyclic animal's; however upon reaching day 17 of the estrous cycle, levels of RBP remain constant and continue to gradually rise throughout gestation. It has also been suggested that ovarian steroids may play a role in regulating uterine RBP expression.
Nanorobots made of DNA origami demonstrated computing capacities and completed pre-programmed task inside the living organism was reported by a team of bioengineers at Wyss Institute at Harvard University and Institute of Nanotechnology and Advanced Materials at Bar-Ilan University. As a proof of concept, the team injected various kinds of nanobots (the curled DNA encasing molecules with fluorescent markers) into live cockroaches. By tracking the markers inside the cockroaches, the team found the accuracy of delivery of the molecules (released by the uncurled DNA) in target cells, the interactions among the nanobots and the control are equivalent to a computer system. The complexity of the logic operations, the decisions and actions, increases with the increased number of nanobots. The team estimated that the computing power in the cockroach can be scaled up to that of an 8-bit computer. A research group at the Indian Institute of Science used nanostructures to develop a platform to elucidate the coaxial stacking between DNA bases. This approach utilized DNA-PAINT based super-resolution microscopy for visualizing these DNA nanostructures and performed DNA binding kinetics analysis to elucidate the fundamental force of base-stacking that helps stabilize the DNA double helical structure. They went on to assemble multimeric DNA origami nanostructures termed as a 'three-point star' into a tetrahedral 3D origami structure. The assembly relied chiefly on base-stacking interactions between each subunit.
== Usage == AUFS is an arbitrary unit of the maximum ultraviolet or visible light absorbance intensity measured by a detector. It can be used in chemical analysis to quantify components in a mixture, as each component's integrated peak area corresponds to their relative abundance. AUFS is given as a number ranging from 0 to 1, where a measurement of 1 AUFS indicates an absorbance reading of 1 at full deflection.
Sources: en.wikipedia.org
Trials differ in patient population, dose schedule, background treatment, and the endpoints used to judge success. Many are small and single-center, so random variation can dominate the reported effects.
Authorization is limited to a small number of countries and covers specific indications such as chronic hepatitis B and vaccine adjuvant use. Availability and labelling differ by jurisdiction.
Most reviews describe it as an immunomodulatory agent with an uncertain clinical effect. They generally call for larger, better-controlled trials before firm conclusions are drawn.
Lyophilized powder is normally kept at minus twenty degrees Celsius or below, in a sealed container, desiccated and away from light. Reconstituted solutions are less stable and are usually refrigerated and used quickly. Repeated temperature cycling should be avoided.